Acumen Pharmaceuticals (ABOS) Stock Statistics & Valuation Metrics

Acumen Pharmaceuticals has a market cap or net worth of $130.84M. The enterprise value is -$43.00M.

Acumen Pharmaceuticals has 60,573,425 shares outstanding. The number of shares has decreased by -2.65% in one year.

Acumen Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -53.87%.

The current PE Ratio of Acumen Pharmaceuticals is ―. Acumen Pharmaceuticals’s PEG ratio is -0.02.

In the last 12 months, Acumen Pharmaceuticals had revenue of 0.00 and earned -102.33M in profits. Earnings per share was -1.71.

In the last 12 months, operating cash flow was -123.66M and capital expenditures -88.00K, giving a free cash flow of -123.75M billion.

Acumen Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Acumen Pharmaceuticals upcoming earnings date is Mar 30, 2026, After Close (Confirmed).

Acumen Pharmaceuticals as a current ratio of 6.46, with Debt / Equity ratio of 3.86%

In the past 12 months, Acumen Pharmaceuticals has paid 0.00 in taxes.

Acumen Pharmaceuticals EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -1.13.

Acumen Pharmaceuticals has $126.61M in cash and marketable securities with $30.84M in debt, giving a net cash position of $95.77M billion.

Gross margin is -1.69%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Acumen Pharmaceuticals is $6.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy